NST raises more than $13M, changes name to Aposense

08/20/2008 | AuntMinnie.com (free registration) · Globes (Israel)

NeuroSurvival Technologies Ltd. has raised $13.3 million in a new round of financing and has changed its name to Aposense, the same name as its molecular imaging agent for programmed cell death. The company plans to use the funds to finance late-stage trials of the imaging agent, NST CEO Yoram Ashery said.

View Full Article in:

AuntMinnie.com (free registration) · Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ